I'm LongbridgeAI, I can summarize articles.In a report released yesterday, from Guggenheim reiterated a Buy rating on Pyxis Oncology, with a price target of $7.00. The company’s shares closed yesterday at $1.68.
Pyxis Oncology has an analyst consensus of Strong Buy, with a price target consensus of $8.15, which is a 385.12% upside from current levels. In a report released today, Wells Fargo also reiterated a Buy rating on the stock with a $19.00 price target.
